Inpatient Tricuspid Valve Transcatheter and Surgical Inpatient Outcomes: A Propensity Matched Analysis

Tricuspid regurgitation (TR) is a common valvular disorder associated with significant morbidity and mortality. While surgical repair (STVr) and replacement (STVR) are established treatments, transcatheter tricuspid valve interventions (TTVI) have emerged as less invasive alternatives. The present study compared inpatient outcomes of TTVI, STVr, and STVR using data from the National Inpatient Sample (2011-2020). A retrospective analysis identified 1830 TTVI, 76 747 STVr, and 19 625 STVR procedures. After propensity score matching, 1655 TTVI-STVr and 1286 TTVI-STVR patient pairs were included. Compared with surgery, TTVI was associated with significantly lower in-hospital mortality (2.4% vs 7.0% STVr; 2.3% vs 11.6% STVR; <i>P</i> < .001), shorter hospital stays (6.9 vs 15.6 days STVr; 7.2 vs 17.6 days STVR; <i>P</i> < .001), and reduced costs. TTVI was associated with lower in-hospital mortality, fewer complications, and shorter hospital stays compared with surgical interventions in this analysis. Given the limitations of retrospective studies, including selection bias and lack of long-term follow-up, these findings require cautious interpretation. Prospective studies are needed to compare the efficacy and durability of TTVI versus surgery for TR.